Literature DB >> 2927482

Identification of high-risk and low-risk subgroups of patients with mitral-valve prolapse.

A R Marks1, C Y Choong, A J Sanfilippo, M Ferré, A E Weyman.   

Abstract

Mitral-valve prolapse is a common cardiac valvular disorder with a wide range of severity and diverse clinical outcomes. The lack of a standard definition of mitral-valve prolapse may explain the variation in reported complication rates. To identify high-risk and low-risk subgroups, we retrospectively analyzed clinical and two-dimensional echocardiographic data from 456 patients with mitral-valve prolapse. Mitral-valve prolapse was defined on the basis of echocardiographic findings as systolic displacement into the left atrium of one or both leaflets beyond the plane of the mitral annulus in the parasternal long-axis view. Two groups of patients were compared: those with thickening of the mitral-valve leaflets and redundancy (designated the classic form; n = 319) and those without leaflet thickening (designated the nonclassic form; n = 137). The two groups were similar in age and sex ratio. Complications or a history of complications was more prevalent in the classic than the nonclassic form: infective endocarditis, 3.5 percent and 0 percent, respectively (P less than 0.02); moderate-to-severe mitral regurgitation, 12 percent and 0 percent (P less than 0.001); and the need for mitral-valve replacement, 6.6 percent and 0.7 percent (P less than 0.02). However, the frequency of stroke was similar in the two groups: 7.5 percent and 5.8 percent (P not significant). We conclude that in a selected population of patients with mitral-valve prolapse, those with the classic form (leaflet thickening and redundancy) are at higher risk than those without these features for the infectious and hemodynamic complications of mitral-valve prolapse, but not for stroke.

Entities:  

Mesh:

Year:  1989        PMID: 2927482     DOI: 10.1056/NEJM198904203201602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  38 in total

1.  A locus for autosomal dominant mitral valve prolapse on chromosome 11p15.4.

Authors:  Lisa A Freed; James S Acierno; Daisy Dai; Maire Leyne; Jane E Marshall; Francesca Nesta; Robert A Levine; Susan A Slaugenhaupt
Journal:  Am J Hum Genet       Date:  2003-04-21       Impact factor: 11.025

2.  Familial clustering of mitral valve prolapse in the community.

Authors:  Francesca N Delling; Jian Rong; Martin G Larson; Birgitta Lehman; Ewa Osypiuk; Plamen Stantchev; Susan A Slaugenhaupt; Emelia J Benjamin; Robert A Levine; Ramachandran S Vasan
Journal:  Circulation       Date:  2014-10-31       Impact factor: 29.690

3.  P-wave dispersion and heart rate variability in children with mitral valve prolapse.

Authors:  Kadir Babaoglu; Gürkan Altun; Köksal Binnetoğlu
Journal:  Pediatr Cardiol       Date:  2011-01-30       Impact factor: 1.655

4.  Infective Endocarditis: Current Guidelines on Prophylaxis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

Review 5.  Assessment of mitral regurgitation.

Authors:  T Irvine; X K Li; D J Sahn; A Kenny
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

Review 6.  Degenerative mitral valve disease with emphasis on mitral valve prolapse.

Authors:  D Pellerin; S Brecker; C Veyrat
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

Review 7.  Cardiology.

Authors:  L D Smith; D J Coltart
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

8.  Echocardiography for mitral valve prolapse.

Authors:  T O Cheng
Journal:  J Gen Intern Med       Date:  1991 Mar-Apr       Impact factor: 5.128

9.  Marfan syndrome and mitral valve prolapse.

Authors:  Arthur E Weyman; Marielle Scherrer-Crosbie
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

10.  Interactions between cardiovascular and cerebrovascular disease.

Authors:  Giuseppe Di Pasquale; Stefano Urbinati; Enrica Perugini; Simona Gambetti
Journal:  Curr Treat Options Neurol       Date:  2012-12       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.